Expert review of gastroenterology & hepatology
-
Expert Rev Gastroenterol Hepatol · Jan 2015
Multicenter StudyPost-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
To evaluate the safety and efficacy of CT-P13 (Remsima(®)) in patients with inflammatory bowel disease (IBD) in South Korea. ⋯ CT-P13 was well tolerated and efficacious in patients with IBD.
-
Expert Rev Gastroenterol Hepatol · Jan 2015
Observational StudyBiosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
To assess the efficacy, tolerability, and safety of CT-P13 (Remsima(®)) in patients with Crohn's disease (CD) or ulcerative colitis (UC). ⋯ CT-P13 is efficacious and well tolerated in patients with CD or UC.